Keywords: fda, marks, abilify, snda, priority, review, drug

FDA marks Abilify sNDA for priority review

Article | 30 July 2007

Print This

US drug major Bristol-Myers Squibb and Japanese strategic partner Otsuka Pharmaceuticals say that the US Food and Drug Administration has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in